Products & Services >> Best Practice Database
>>Archived Research Alerts
>>September 2020 Research
SEPTEMBER 2020 Research Alert
This month we added five new studies to the Best Practice Database, the research repository for Best Practices, LLC. This month's new studies focus on three topical areas: using DTC campaigns quicker after launch; the use of social media to support an NDA; and maximizing the impact of Analytics and Insights teams. The first research is a case study on Skyrizi and how AbbVie quickly launched its DTC campaign to boost uptake. The second document is also a case study, this one on Addyi and how Sprout used social media to support its NDA. The last three studies focus on Analytics and Insights teams and different ways to maximize the impact of this group, including core responsibilities, capabilities and Innovation Centers of Excellence.
The new Best Practices, LLC studies listed below under Newly Added Research explore how leading companies have made their operations more effective across these different areas.
|Skyrizi Case Study: How Compressing Cycle Time from Launch to DTC helps Support Sales Uptake of a Rising new Blockbuster Product (5629)
This case study examines how compressing cycle time from launch to DTC helped AbbVie lift sales uptake of Skyrizi, the rising new blockbuster product in the plaque psoriasis therapeutic area.
|Addyi (flibanserin): How an Upstart Biopharma Used Social Media and Policy Tools to Support its NDA Approval - and a $1 Billion Payday (5630)
This case study examines how Sprout utilized social media and policy tools to pressure regulators to reconsider previous objections to Addyi and to ultimately win approval for the drug.
|Maximizing the Impact of Analytics and Insights Teams Across the Biopharma Organization: Core Responsibilities, Value Delivery and Internal Branding Programs (5641)
Best Practices, LLC undertook this benchmarking research to help A&I teams within biopharma companies make decisions to maximize its impact and enhance its standing not only with commercial teams, but also with medical affairs, HEOR, market access, corporate and other key internal customers.
|Maximizing the Impact of Analytics and Insights Teams Across the Biopharma Organization: Optimizing Analytics Capabilities (5642)
This study shares how Analytics & Insights teams within biopharma companies can leverage their analytics and talent to provide effective strategic consultation, focus resources, optimize analytics capabilities, and scale successes.
|Maximizing the Impact of Analytics and Insights Teams Across the Biopharma Organization: Innovation Centers of Excellence, Patient Engagement and COVID-19 Support (5643)
This study examines the role played by A&I teams in supporting Innovation Centers of Excellence and patient engagement, and the new opportunities and challenges that have emerged for A&I groups as a result of COVID-19.